Anixa Biosciences, Inc. Stock

Equities

ANIX

US03528H1095

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
3.08 USD +2.33% Intraday chart for Anixa Biosciences, Inc. -2.84% -20.62%
Sales 2024 * - Sales 2025 * - Capitalization 96.02M
Net income 2024 * -14M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-6.84 x
P/E ratio 2025 *
-6.69 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.1%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Anixa Biosciences, Inc.

1 day+2.33%
1 week-2.84%
Current month-1.28%
1 month-4.64%
3 months-37.14%
6 months-4.94%
Current year-20.62%
More quotes
1 week
3.00
Extreme 3
3.20
1 month
3.00
Extreme 3
3.48
Current year
3.00
Extreme 3
5.13
1 year
2.75
Extreme 2.75
5.13
3 years
2.30
Extreme 2.3
6.45
5 years
1.33
Extreme 1.33
8.09
10 years
0.60
Extreme 0.6001
10.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 12-10-31
Director of Finance/CFO 57 16-10-31
Corporate Officer/Principal 69 21-09-06
Members of the board TitleAgeSince
Director/Board Member 79 99-06-30
Chief Executive Officer 59 12-10-31
Director/Board Member 63 19-10-22
More insiders
Date Price Change Volume
24-04-22 3.01 -3.53% 57,975
24-04-19 3.12 +0.65% 32,692
24-04-18 3.1 +1.64% 58,503
24-04-17 3.05 -3.79% 72,904
24-04-16 3.17 +0.32% 78,207

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.01 USD
Average target price
12 USD
Spread / Average Target
+298.67%
Consensus